ReviewFrontiers in immunology2026
From thresholds to trajectories: a perspective on reframing alloimmune risk for computational modeling in solid organ transplantation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunological risk prediction in solid organ transplantation has long depended on threshold-based representation of histocompatibility data: donor-specific antibodies (DSA) reported as positive or negative, mean fluorescence intensity (MFI) assessed by fixed cutoffs, molecular mismatch assigned at transplantation, and assays interpreted at a single time point. Although practical, these conventions simplify the complex and dynamic nature of the immune response. In this perspective, we argue that as machine learning (ML) algorithms and computational approaches enter the field of transplant immunology, we need to focus on whether the inputs that feed into these tools and models reflect how alloimmunity actually behaves. We propose treating alloimmune risk as a time-indexed alloimmune state, updated whenever new data are available, across four domains: antibody profile, molecular mismatch and predicted immunogenicity, recipient immune context, and graft context. Within this framework, the features that experienced clinicians and histocompatibility experts already track (e.g., DSA velocity, persistence, epitope spreading, concordance with graft injury) become computable rather than implicit. We discuss how moving from thresholds to trajectories impacts model design, why HLA laboratory expertise becomes more important rather than less, and why interpretability, regulation, and external validation should precede clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.